In the last few years there has been increasing awareness of the link between bisphosphonates and osteonecrosis of the jaw (ONJ). As more data emerge, it is important to share current knowledge and new guidelines.
As some dental practitioners may not be familiar with this family of drugs, it is important to discuss the growing range of bisphosphonates and their uses so that patients who are at risk of developing ONJ are identified.
Bisphosphonates are pyrophosphate analogues that inhibit osteoclastic function and thereby decrease bone resorption. Medically, they are useful drugs in the treatment of osteoporosis, Paget's disease, hypercalcaemia and in patients with cancer. In this respect, in cancers that metastasize to the bone, bisphosphonates reduce risks of complications, such as spinal cord compression, fractures and bone pain. However, the vast majority of oral bisphosphonate prescriptions are for patients with osteoporosis. It is important for dentists to realize that osteoporosis is a serious condition which leads to significant health problems and expense to health and social services, costing the country £1.8 billion every year. 1 It leads to 180,000 fragility fractures in the UK annually, including 70,000 hip fractures, which are associated with morbidity and mortality. 2 Patients with cancer, especially those receiving anti-cancer drugs, are often also given bisphosphonates, usually in intravenous formulations and in higher doses than used for osteoporosis and other non-cancer conditions. risedronate, tiludronate, ibandronate, pamidronate and zoledronate. The latter two are available only in intravenous form and ibandronate can be used orally or intravenously.
Owing to the rising concern over bisphosphonate associated ONJ, a working party of 24 members from US National Institutes of Health and Canadian Institutes of Health Research was appointed by the American Society for Bone and Mineral Research (ASBMR). These experts covered a range of disciplines, including histology, epidemiology, oromaxillofacial, rheumatology, oncology and other essential medical fields. The important messages from the working party report 3 are summarized below.
Definitions

A confirmed case of bisphosphonate-associated ONJ
This was defined as 'an area of exposed bone in the maxillofacial region that did not heal within 8 weeks after identification by a healthcare worker, in a patient who was receiving, or had been exposed to, a bisphosphonate and had not had radiation therapy to the craniofacial region' . 
Dentures
Need good fitting dentures. 5 Good fitting dentures possibly with soft lining to prevent trauma.
5
Endodontics Avoid apical surgery. Conventional orthograde Avoid apical surgery. Conventional endodontics recommended rather than extraction orthograde endodontics recommended where possible. Good coronal seal maintenance rather than extraction where possible. important.
Good coronal seal maintenance important.
Implants
Currently not contra-indicated if taking Not recommended and avoid elective bisphosphonates but prudent to gain informed surgery such as tori removal. consent which should be documented (risk assessment). 
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A suspected case of bisphosphonate-associated ONJ This was defined as 'an area of exposed bone in the maxillofacial region that had been identified by a healthcare provider and had been present for < 8 weeks in a patient who was receiving, or had been exposed to, a bisphosphonate and had not had radiation therapy to the craniofacial region' .
Suspected cases of bisphosphonate-associated ONJ should be followed up and referred to a specialist. Differential diagnosis includes:
Periapical pathology caused by a carious infection;
Tumours; Mucositis; Infectious osteomyelitis; Neuralgia-inducing cavitational osteonecrosis (NICO).
Similarly, other mucosal oral conditions, such as periodontal disease, may show exposure of bone as above but, without a history of bisphosphonate use, they cannot fall into the category of bisphosphonate-associated ONJ.
Incidence of bisphosphonate associated ONJ
Both published and unpublished data on ONJ were reviewed by the working party. Current knowledge on incidence suggests that:
The incidence of ONJ in oral bisphosphonate therapy for osteoporosis is low (between 1 in 10,000 to 1 in 100,000), but it was recognized that this figure could turn out to be higher as more data are collected.
Cancer patients on high dose intravenous bisphosphonates were more at risk (ranging from 1 in 10 to 1 in a 100 patients), depending upon the duration of the bisphosphonate treatment. 
Clinical features of ONJ
Diagnosis of ONJ
It is essential to refer ONJ suspected/diagnosed patients, together with a panoramic radiograph (if available), to a specialist. In general dental practice
Pain
Must be dealt with first appropriately. Other considerations 1. In advanced ONJ in patients with limited ability to eat additional nutritional supplements important, eg tube feeding. 2. Hyperbaric Oxygen: effectiveness of this procedure has not been established. CT for differential diagnosis; Cone beam CT gives detail on thickness of cortex, integrity and marrow involvement, cancellous bone mineral density (BMD) and irregularities after tooth extraction.
Soft tissue and bone marrow imaging techniques
MRI recognizes ischaemic areas with the use of contrasting agents but it may give false positives.
Functional/physiological tests
Technetium-99 radioisotope scintigraphy -in patients with metastatic bone disease, where clinically indicated;
Positron emission tomography -not very useful as poor resolution with high radiation dose;
Bone resorption markers such as the collagen telopeptide (CTX) may be of some value in assessing the risk of bisphosphonate-induced osteonecrosis by indicating oversuppression of bone turnover. 4 
Biopsy
In most cases, biopsy is not necessary and may even be detrimental to bone healing. However, when there is a history of parenteral bisphosphonate therapy for metastatic cancer, then the possibility of metastases to the jaw should be seriously considered and, if no biopsy is taken, the reason should be recorded in the patient's notes.
However, there is a need for more research to develop diagnostic procedures further.
Prevention of ONJ
All patients with osteoporosis or other non-malignant disease will need good oral hygiene and regular routine dental examinations and hygiene. For those patients taking bisphosphonates for more than 3 years, recommended actions are shown in Table 1 . There are also important differences in approach to patients taking bisphosphonates for osteoporosis and nonmalignant disease compared to patients with malignancy who are starting or already taking bisphosphonates.
Management of bisphosphonate-associated ONJ
Once ONJ has developed, managing the condition can be challenging. After diagnosis, the important aspects of treatment are shown in Table 2 .
General recommendations of the working party
It is important to have good communication between physicians and dentists. Patients should be encouraged by their physicians to inform their dentist if they are taking a bisphosphonate. All patients should be informed of benefits and potential risks of bisphosphonates, including ONJ, the signs and symptoms of ONJ, as well as risk factors. Patients should be advised to maintain good oral hygiene and have regular routine dental visits. In areas where there is limited access to dental care, patients and physicians should be educated about ONJ. In this situation, it is even more important to maintain good oral homecare, as dental disease prevention is essential.
Conclusions
As further data are published, we will learn more about the true extent of ONJ. It is important to recognize that ONJ is not common in patients who are given bisphosphonates for osteoporosis, but the incidence is much higher in cancer patients and those receiving bisphosphonates as part of their anti-cancer drug regime. More studies are essential on the prevalence, risk factors, morbidity and cost implications of ONJ. Management of ONJ is difficult and expensive. Prevention, wherever possible, is therefore the key. This will have to start at primary care levels. Education and regular updated guidelines for general practitioners are important to try and limit the impact of ONJ.
